Levetiracetam Neogen

Levetiracetam, the active ingredient in Levetiracetam Neogen, is an antiepileptic presented as an intravenous solution for intravenous use. It treats partial‑onset seizures, generalized tonic‑clonic seizures, and epilepsy in patients who require seizure control.

GNH USA supplies Levetiracetam Neogen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Levetiracetam is an antiepileptic drug that acts on neuronal excitability to reduce seizure activity. - Partial‑onset seizures: decreases frequency of focal seizures. - Generalized tonic‑clonic seizures: helps control convulsive episodes. - Epilepsy (overall): provides adjunctive therapy for patients with refractory epilepsy.

Levetiracetam may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Dizziness - Somnolence - Fatigue - Headache - Nausea - Irritability

Serious or Rare Side Effects: - Stevens‑Johnson syndrome or severe skin reactions - Suicidal ideation or severe depression - Blood dyscrasias such as neutropenia - Anaphylactic reactions - Severe mood changes - Multi‑organ hypersensitivity

When prescribing Levetiracetam, clinicians should consider several safety aspects. - Renal impairment: adjust dosing based on renal function. - Hepatic impairment: monitor liver enzymes and clinical response. - Concomitant CNS depressants: may increase sedation. - Pregnancy: risk unknown; discuss benefits and risks with the patient. - Driving or operating machinery: caution due to possible dizziness or drowsiness. - Store at ambient temperature: keep in original packaging, protect from moisture and direct light.

Levetiracetam can interact with other medicines, influencing its effectiveness or safety.

Major Interactions (Avoid): - Carbamazepine: enzyme induction reduces levetiracetam levels. - Phenytoin: increases metabolism, lowering therapeutic effect. - Rifampin: strong inducer that may decrease plasma concentrations.

Moderate Interactions (Monitor Closely): - Valproic acid: may raise levetiracetam concentrations. - CNS depressants (e.g., benzodiazepines): enhanced sedation risk. - Alcohol: additive CNS depressive effects.